Industry context
Tyra Biosciences Inc [TYRA]
Last Updated 25 Jun 2026 @ 16:00 (Exchange is closed)
Last: $30.94
1.88%
0.41 (↑)
GaG Algo Score™
v1.0
Short
0.41 (↑)
Medium
0.44 (↑)
Long
1.67 (↑)
BUY
67.35%
return 23.92%
SELL
72.00%
return 45.55%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 17.15% | 17.15% | 6.46% |
| Loss % | -21.92% | -21.92% | 13.36% |
| Duration | 15.5d | 14d | 7.6d |
| Total Pivots Found | 5 |
| Gain/Loss Legs | 4 (2 Gain / 2 Loss) |
| Last Pivot | Top @ $30.94 on 2026-06-25 |
| Change since Last Pivot | $0.00 (0.00%) |
Next Pivot Prediction Last: $30.94
| Predicted Next Type | Bottom |
| Predicted Price (Avg) | $24.16 |
| Predicted Price (Median) | $24.16 |
| Predicted Price Range (~68%) | $20.02 - $28.29 |
| Change to Avg Target | $-6.78 (-21.92%) |
| Predicted Date (Avg) | 2026-07-10 |
| Predicted Date Range (~68%) | 2026-07-02 - 2026-07-18 |
| Basis | Based on 2 historical losses (Avg: -21.92%, Median: -21.92%, StdDev of Abs: 13.36%) and duration (Avg: 15.5 days, StdDev: 7.6 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Tyra Biosciences Inc rose moderately, up 1.88% on Thursday.
Tyra Biosciences Inc (TYRA) stock price experienced a significant rise on Thursday after the stock rose $0.570 (1.88%) from the previous session on below-average volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.46%. With 634 165 shares traded, volume yesterday reached $19.62M. This was 465 shares more than the prior day. Compared to the 10-day average of 1.04M shares, volume was the same as the average.
Tyra Biosciences Inc signals
There is no conclusive signals given from RSI. The price is above both moving averages, but the short-term average remains below the long-term average; upward momentum is present but not yet fully confirmed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (3.3%), medium- (3.3%), and long-term (3.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Tyra Biosciences Inc Support & Resistance Levels
The stock is trading above the closest support level at $30.40. approximately $0.540 (1.75%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s130.4 -
Tyra Biosciences Inc Evaluation
- Short score: 0.41
- Medium score: 0.44
- Long score: 1.67
Ownership flow
GetAGraph InsiderPower
Transactions
167
Buy power
143.16M
Sell power
29.61M
Reliability
100/100
Buy / sell
4.84
Hist. corr.
-0.90
Latest signal
Buy 2026-05-20
Director 69
Officer 55
Executive 40
Other 3
2026-05-28
Ra Capital Management, L.p. Director
Buy 13 160
2026-05-28
Verjee Rehan Director
Buy 13 160
2026-05-28
Moran Susan Director
Buy 13 160
2026-05-28
Simson Jake Director
Buy 13 160
2026-05-28
Gulfo Adele M. Director
Buy 13 160
2026-05-28
More Robert J Director
Buy 13 160
Relationship map
Correlation snapshot
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.93% <strong>$31.13</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
17.39%
Of outstanding shares
Short float
25.47%
Of tradable float
Days to cover
13.12
Short interest divided by average volume
Squeeze probability
98.20%
+15.08% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
7
EPS misses
3
Avg. surprise
5.20%
Tyra Biosciences Inc Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Beat
Q2/2023
Miss
Q3/2023
Miss
Q4/2023
Beat
Q1/2024
Beat
Q2/2024
Miss
Q3/2024
Beat
Q4/2024
Beat
Q1/2025
Waiting
Q2/2025
Waiting
Q3/2025
Tyra Biosciences Inc Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Q3/2025 | - | - | Waiting | - | - | Waiting |
| 2025-08-06 | Q2/2025 | $-0.550 | - | Waiting | - | - | Waiting |
| 2025-05-08 | Q1/2025 | $-0.490 | $-0.470 | Beat 4.08% | - | - | Waiting |
| 2025-03-27 | Q4/2024 | $-0.480 | $-0.430 | Beat 10.42% | - | - | Waiting |
| 2024-11-07 | Q3/2024 | $-0.400 | $-0.410 | Miss -2.50% | - | - | Waiting |
| 2024-08-07 | Q2/2024 | $-0.410 | $-0.320 | Beat 21.95% | - | - | Waiting |
| 2024-05-09 | Q1/2024 | $-0.460 | $-0.350 | Beat 23.91% | - | - | Waiting |
| 2024-03-19 | Q4/2023 | $-0.480 | $-0.530 | Miss -10.42% | - | 502 000 | Waiting |
| 2023-11-07 | Q3/2023 | $-0.350 | $-0.490 | Miss -40.00% | - | - | Waiting |
| 2023-08-10 | Q2/2023 | $-0.340 | $-0.310 | Beat 8.82% | - | - | Waiting |
| 2023-05-04 | Q1/2023 | $-0.370 | $-0.280 | Beat 24.32% | - | - | Waiting |
| 2023-03-22 | Q4/2022 | $-0.350 | $-0.310 | Beat 11.43% | - | - | Waiting |
Analyst view
Analyst targets
Consensus
$50.50
Median
$51.50
Low
$42.00
High
$59.00
News flow
Latest company news
Market coverage
prnewswire.com TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY May 21, 2026 fool.com Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares May 17, 2026 seekingalpha.com Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript May 13, 2026 prnewswire.com Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights May 13, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Currency
USD
Tyra Biosciences Inc is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology Its flagship product candidate TYRA300 is a highly selective inhibitor of fibroblast growth factor receptor FGFR3 specifically engineered for the treatment of muscleinvasive bladder cancer Beyond this the company is advancing a pipeline of programs addressing other critical conditions including FGFR2related intrahepatic cholangiocarcinoma FGFR3associated achondroplasia REarranged during transfection RET kinase aberrations and various FGFR4driven cancers Tyra also leverages its proprietary SNAP platform designed to accelerate structural drug design through an iterative molecular snapshot approach Founded in 2018 Tyra Biosciences maintains its headquarters in Carlsbad California
Navigation